Accueil・Liste d'Actions・Alvotech SA

Alvotech SA

Ouvert

SecteurSoins de santé

4.05 -0.74

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.98

Max

4.13

Chiffres clés
By Trading Economics
Revenu	110M 1M
Ventes	-60M 106M
P/E Moyenne du Secteur	42.4 57.002
BPA	-0.09
Marge bénéficiaire	0.973
Employés	1,279
EBITDA	167M 52M

Recommandations
By TipRanks
Recommandations	Vente
Prévisions sur 12 Mois	-2.2% downside

Dividendes
By Acuity
Prochains Résultats	19 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	261M 1.3B
Ouverture précédente	4.79
Clôture précédente	4.05

Sentiment de l'Actualité

By Acuity

40%

60%

134 / 340 Classement par Healthcare

Alvotech SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

12 août 2026, 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

11 août 2026, 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

10 août 2026, 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

6 août 2026, 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

5 août 2026, 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

4 août 2026, 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

3 août 2026, 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

31 juil. 2026, 21:02 UTC

Alvotech SA shares declined in after-market trading, reversing six days of gains. No specific news was identified to explain the price movement.

30 juil. 2026, 20:10 UTC

Alvotech SA shares are higher during Thursday's session, reflecting broader market movements amid mixed economic signals and maintaining a position above the 20-day moving average.

29 juil. 2026, 19:04 UTC

News

Social Media

Alvotech SA's FDA inspection results in a Voluntary Action Indicated classification. Shares are trading higher as the company advances its biosimilar pipeline.

28 juil. 2026, 19:56 UTC

Alvotech SA shares are higher today, reaching a high of 6.17%. The stock remains below its 20-day moving average with no specific news identified.

27 juil. 2026, 19:31 UTC

Alvotech SA shares are higher today, rebounding from an earlier session low. This follows a positive trend since Friday's close amid declining oil prices.

24 juil. 2026, 19:51 UTC

Alvotech SA shares are lower today, continuing a trend of weakness amid broader market pressures and three consecutive lower daily closes.

22 juil. 2026, 18:31 UTC

Alvotech SA shares are lower, continuing a decline since Tuesday. Broader market sentiment is impacted by geopolitical tensions and rising crude oil prices.

21 juil. 2026, 19:16 UTC

Alvotech SA shares are higher during Tuesday's session amid a broader market recovery, driven by renewed interest in AI stocks and upcoming tech earnings.

20 juil. 2026, 19:31 UTC

Alvotech SA shares are lower today, with no specific news identified. Broader market weakness includes a decline in the US 10Y Treasury Bond index.

Comparaison

Variation de prix

Alvotech SA prévision

Objectif de Prix

By TipRanks

-2.2% baisse

Prévisions sur 12 Mois

Moyen 4 USD -2.2%

Haut 4 USD

Bas 4 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Vente

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

134 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.